Larimar reports Q3 2026 results, confirms BLA submission and 2027 launch targetsNov 16Regulatory decisionLarimar Therapeutics, Inc.nomlabofuspUpdated
Larimar Therapeutics names John B. Harlow Jr. president and COOSep 29PeopleLarimar Therapeutics, Inc.
Larimar registers Phase 3 FORWARD-FA trial of nomlabofusp for Friedreich's ataxiaAug 21Trial updateLarimar Therapeutics, Inc.nomlabofusp
Larimar reports Q2 2026 update on nomlabofusp BLA, Phase 3 timing and cashAug 4Quarterly updateLarimar Therapeutics, Inc.nomlabofusp
Larimar submits first BLA module for nomlabofusp in Friedreich's ataxia, reports open-label dataJun 29Regulatory decisionLarimar Therapeutics, Inc.nomlabofusp